Cytokinetics (CYTK)
Cytokinetics Statistics
Share Statistics
Cytokinetics has 119.19M shares outstanding. The number of shares has increased by 3.27% in one year.
| Shares Outstanding | 119.19M |
| Shares Change (YoY) | 3.27% |
| Shares Change (QoQ) | 0.34% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 116.04M |
| Failed to Deliver (FTD) Shares | 684 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 14.33M, so 12.1% of the outstanding shares have been sold short.
| Short Interest | 14.33M |
| Short % of Shares Out | 12.1% |
| Short % of Float | 18.43% |
| Short Ratio (days to cover) | 8.03 |
Valuation Ratios
The PE ratio is -8.94 and the forward PE ratio is -8.45. Cytokinetics's PEG ratio is 2.56.
| PE Ratio | -8.94 |
| Forward PE | -8.45 |
| PS Ratio | 285.13 |
| Forward PS | 2.9 |
| PB Ratio | -38.91 |
| P/FCF Ratio | -13.18 |
| PEG Ratio | 2.56 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Cytokinetics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.17, with a Debt / Equity ratio of -5.14.
| Current Ratio | 6.17 |
| Quick Ratio | 6.17 |
| Debt / Equity | -5.14 |
| Debt / EBITDA | -1.41 |
| Debt / FCF | -1.74 |
| Interest Coverage | -6.2 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $37.1K |
| Profits Per Employee | $-1.18M |
| Employee Count | 498 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -42.8% in the last 52 weeks. The beta is 0.94, so Cytokinetics's price volatility has been higher than the market average.
| Beta | 0.94 |
| 52-Week Price Change | -42.8% |
| 50-Day Moving Average | 42.77 |
| 200-Day Moving Average | 50.37 |
| Relative Strength Index (RSI) | 42.32 |
| Average Volume (20 Days) | 1.98M |
Income Statement
In the last 12 months, Cytokinetics had revenue of 18.47M and earned -589.53M in profits. Earnings per share was -5.26.
| Revenue | 18.47M |
| Gross Profit | 18.47M |
| Operating Income | -536.25M |
| Net Income | -589.53M |
| EBITDA | -493.48M |
| EBIT | -503.01M |
| Earnings Per Share (EPS) | -5.26 |
Balance Sheet
The company has 94.86M in cash and 695.45M in debt, giving a net cash position of -600.59M.
| Cash & Cash Equivalents | 94.86M |
| Total Debt | 695.45M |
| Net Cash | -600.59M |
| Retained Earnings | -2.7B |
| Total Assets | 1.4B |
| Working Capital | 928.27M |
Cash Flow
In the last 12 months, operating cash flow was -395.89M and capital expenditures -3.91M, giving a free cash flow of -399.8M.
| Operating Cash Flow | -395.89M |
| Capital Expenditures | -3.91M |
| Free Cash Flow | -399.8M |
| FCF Per Share | -3.57 |
Margins
Gross margin is 100%, with operating and profit margins of -2902.72% and -3191.11%.
| Gross Margin | 100% |
| Operating Margin | -2902.72% |
| Pretax Margin | -3191.11% |
| Profit Margin | -3191.11% |
| EBITDA Margin | -2671.23% |
| EBIT Margin | -2902.72% |
| FCF Margin | -2164.1% |
Dividends & Yields
CYTK does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CYTK is $78, which is 105.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $78 |
| Price Target Difference | 105.7% |
| Analyst Consensus | Buy |
| Analyst Count | 18 |
Stock Splits
The last stock split was on Jun 25, 2013. It was a backward split with a ratio of 1:6.
| Last Split Date | Jun 25, 2013 |
| Split Type | backward |
| Split Ratio | 1:6 |
Scores
| Altman Z-Score | -1.24 |
| Piotroski F-Score | 3 |